Search 

Lilly Asia Ventures is the venture capital arm of Eli Lilly that focuses on investments in the life sciences in Asia, particularly China. The firm was established in 2008 and is based in Shanghai, China. The firm is stage agnostic; investing in early, growth, and up to pre-IPO opportunities. The firm’s investment size is USD 5-20 million per company. The firm primarily invests in companies in China, but is open to companies across Asia-Pacific as long as there is some sort of China angle. The firm is actively seeking new investment opportunities.

Lilly Asia Ventures primarily focuses on therapeutics but is also interested in medical devices, diagnostics, animal health, and biotech other. The firm is most interested in products that will have a significant impact on medical care in China. For therapeutics, the firm seeks best-in-class or first-in-class products. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA. Historically, the firm invests in therapeutics for oncology, inflammatory diseases, and metabolic disorders.

Longitude Capital is a private equity group founded in 2006 with offices in Menlo Park, California and Greenwich, Connecticut. The firm has $700 million in assets and has raised two funds, with the most recent fund closing at $385m in 2012. Longitude makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. Longitude Capital primarily invests in North America and the European Union but may also consider opportunities in the Middle East.

McDermott Will & Emery is a premier international law firm with a unique focus in representing life sciences companies and investors in a wide variety of transactional, intellectual property and regulatory matters.  Through our Life Sciences Entrepreneurs Acceleration Program ("LEAP") we provide early stage medical device, pharmaceutical, biotechnology and diagnostic companies access to sophisticated legal services.  Learn more here: http://www.mwe.com/leap/

Emerging, middle-market and established companies alike require sophisticated legal representation that is cost-effective and capable of responding to the rapidly changing demands of regulators and customers. As counsel to domestic and global life sciences companies at every stage of development, the Life Sciences industry group at McGuireWoods offers clients a single, coordinated team of lawyers with deep, varied experience. Our clients recognize that they are treated as firm clients and not as those of a single practitioner or office location.

We counsel clients in all major areas of law affecting life sciences businesses and at every step in the product lifecycle. We provide guidance on corporate transactions and matters involving company structure and formation, financing, facilities acquisition and leasing, and vendor contracts. We have extensive experience in healthcare and life sciences-related regulatory requirements, including compliance audits and policies, FDA notification and approvals, development of pricing programs, and reimbursement and third-party payor processes.

Regulatory policies walk hand in hand with legislative mandates. In conjunction with our full-service public affairs subsidiary, McGuireWoods Consulting, we provide strategic communications and government relations guidance that helps businesses and industry coalitions shape pending legislation and respond to state and federal initiatives.

When disputes or law enforcement investigations arise, we provide aggressive defense against allegations of theft, product liability and mass torts. We represent clients facing government inquiries and administrative actions involving a broad range of issues, from securities disclosures and financial accounting rules to data privacy, antitrust and other compliance requirements. We also investigate and vigorously pursue counterfeiters, gray marketers and abusers of supply chain systems.

As life sciences businesses grow and transform, capital sourcing and other forms of financing become an important concern. We represent clients in negotiations with private equity investors, commercial banks and other financial institutions. Similarly, our depth of experience in public offerings and middle-market mergers and acquisitions adds value to growth and technology companies when exploring liquidity events.

While life sciences businesses share many of the same concerns as companies in other industries, these issues must be addressed in the context of this highly regulated sector of the economy. Our multidisciplinary team of lawyers provides broad-spectrum, coordinated counsel on all major areas of law affecting clients’ operations and strategy. These core areas of service include labor and employment, intellectual property, state and local taxation, and international trade. Our experience in these and other areas of law enables us to provide prompt, effective counsel in the dynamic life sciences marketplace.

The Office of Translational Alliances and Coordination (OTAC) at the National Heart, Lung, and Blood Institute supports the development of innovative biomedical products to address unmet medical needs in the heart, lung, blood and sleep fields.  OTAC is home to the NHLBI's small business programs (SBIR and STTR) and the NIH Centers for Accelerated Innovations.

The NHLBI's SBIR and STTR programs comprise one of the largest sources of early-stage capital for U.S. small business, acting as engines of innovation for developing and commercializing novel technologies and products that aid in the prevention, diagnosis, and treatment of heart, lung, blood, and sleep diseases and disorders. The NHLBI provides grant and contract funding opportunities and resources to support small businesses performing research and development on technologies related to the mission of NHLBI. With an annual budget of $85M, the NHLBI funds about 200 companies each year through the Institute's small business programs.

The NIH Centers for Accelerated Innovations accelerate translation of scientific discovery into commercial products that improve health for patients. This unique public-private partnership is changing the way discoveries with scientific and commercial potential are identified and developed.

Comprising 10 investment professionals, Omnes Capital’s venture capital team acquires minority stakes in young companies with high growth potential. Its main areas of interest are financing innovative business ventures in the information technology and life sciences sectors (drug development, diagnostics, medical devices, bioproduction).

For 12 years, Omnes Capital has managed FCPI mutual funds (French regulated mutual funds investing in innovative companies).